Sergliflozin etabonate
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| 2-(4-methoxybenzyl)phenyl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Routes | Oral |
| Identifiers | |
| CAS number | 408504-26-7 |
| ATC code | None |
| PubChem | CID 9824918 |
| Chemical data | |
| Formula | C23H28O9 |
| Mol. mass | 448.463 g/mol |
| SMILES | eMolecules & PubChem |
 (what is this?) (verify) |
|
Sergliflozin etabonate (INN/USAN,[1][2] codenamed GW869682X) is an investigational anti-diabetic drug being developed by GlaxoSmithKline. It did not undergo further development after phase II.[citation needed]
[edit] Method of action
Sergliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.[3][4]
[edit] References
- ^ World Health Organization (2008). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 59". WHO Drug Information 22 (1): 66. http://whqlibdoc.who.int/druginfo/INN_2008_list59.pdf.
- ^ "Statement on a nonproprietary name adopted by the USAN council: Sergliflozin etabonate". American Medical Association. http://www.ama-assn.org/ama1/pub/upload/mm/365/sergliflozin_etabona.pdf. Retrieved 2008-08-10.
- ^ Katsuno K, Fujimori Y, Takemura Y, et al. (January 2007). "Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level". J Pharmacol Exp Ther 320 (1): 323–30. doi:10.1124/jpet.106.110296. PMID 17050778. http://jpet.aspetjournals.org/cgi/content/full/320/1/323.
- ^ Prous Science: Molecule of the Month November 2007
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
